Last reviewed · How we verify
NCT05455931: PROSPER
Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)
trial testing Poteligeo in Mycosis Fungoides and Sézary Syndrome in 73 participants. Participants enrolled and being followed up; not accepting new ones.
7 August 2025
Quick facts
| Lead sponsor | Kyowa Kirin Pharmaceutical Development Ltd |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 73 |
| Start date | 9 November 2022 |
| Primary completion | 7 August 2025 |
| Estimated completion | 7 August 2025 |
| Sites | 19 locations across Italy, Netherlands, United Kingdom, United Arab Emirates, United States, Spain |
Drugs / interventions tested
- Poteligeo — full drug profile →
Conditions studied
- Mycosis Fungoides and Sézary Syndrome — all drugs for Mycosis Fungoides and Sézary Syndrome →
Sponsor
Kyowa Kirin Pharmaceutical Development Ltd — full company profile →
Who can join
18 and older, any sex, with Mycosis Fungoides and Sézary Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, observational, non-interventional, international, multi-center, mixed methods study that will involve the integration of quantitative and qualitative data in patients with MF/SS treated with Poteligeo.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
Quadri I, Reneau JC, Hanel W, Chung CG. · · 2023 · cited 8× · PMID 38022633 · DOI 10.3389/fimmu.2023.1291259
Verify or expand the search:
- PubMed search for NCT05455931
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Kyowa Kirin Pharmaceutical Development Ltd trials
Trials by the same sponsor.
- NCT05181839 — A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth · completed
- NCT04819490 — A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLH · completed
- NCT04188964 — Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age · Phase 1, PHASE2 · completed
- NCT03920072 — Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH · Phase 3 · completed
- NCT03638440 — Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05455931 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kyowa Kirin Pharmaceutical Development Ltd
- Last refreshed: 4 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05455931.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing